Literature DB >> 26173838

Ponatinib: Accelerated Disapproval.

Justin F Gainor1, Bruce A Chabner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26173838      PMCID： PMC4524765          DOI： 10.1634/theoncologist.2015-0253

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

Review 1.  Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

Review 2.  Accelerated approval of oncology products: the food and drug administration experience.

Authors:  John R Johnson; Yang-Min Ning; Ann Farrell; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  J Natl Cancer Inst       Date:  2011-03-21       Impact factor: 13.506

3.  Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.

Authors:  David J Dorer; Ronald K Knickerbocker; Michele Baccarani; Jorge E Cortes; Andreas Hochhaus; Moshe Talpaz; Frank G Haluska
Journal:  Leuk Res       Date:  2016-07-22       Impact factor: 3.156

4.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

5.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245
  5 in total
  23 in total

1.  Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.

Authors:  Anand P Singh; Michael S Glennon; Prachi Umbarkar; Manisha Gupte; Cristi L Galindo; Qinkun Zhang; Thomas Force; Jason R Becker; Hind Lal
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

2.  Breakthrough Drugs and Turtle Soup.

Authors:  Bruce A Chabner
Journal:  Oncologist       Date:  2015-07-16

3.  Inhibition of Necroptosis to Prevent Long-term Cardiac Damage During Pneumococcal Pneumonia and Invasive Disease.

Authors:  Sarah M Beno; Ashleigh N Riegler; Ryan P Gilley; Terry Brissac; Yong Wang; Katherine L Kruckow; Jeevan K Jadapalli; Griffin M Wright; Anukul T Shenoy; Sara N Stoner; Marcos I Restrepo; Jessy S Deshane; Ganesh V Halade; Norberto González-Juarbe; Carlos J Orihuela
Journal:  J Infect Dis       Date:  2020-11-09       Impact factor: 5.226

4.  Disclosing accelerated approval on direct-to-consumer prescription drug websites.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Kathleen T David; Nisha J Patel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-09-28       Impact factor: 2.890

5.  Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.

Authors:  Hirohisa Nakamae; Shin Fujisawa; Michinori Ogura; Toshiki Uchida; Yasushi Onishi; Masafumi Taniwaki; Atae Utsunomiya; Kosei Matsue; Yasushi Takamatsu; Kensuke Usuki; Mitsune Tanimoto; Yoji Ishida; Kazuteru Ohashi; Li Li; Masafumi Miyoshi
Journal:  Int J Hematol       Date:  2017-03-24       Impact factor: 2.490

6.  Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.

Authors:  Elizabeth Larocque; N Naganna; Xiaochu Ma; Clement Opoku-Temeng; Brandon Carter-Cooper; Gaurav Chopra; Rena G Lapidus; Herman O Sintim
Journal:  Future Med Chem       Date:  2017-05-11       Impact factor: 3.808

Review 7.  Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.

Authors:  Veerandra Kumar; Priyanka Singh; Sonu Kumar Gupta; Villayat Ali; Malkhey Verma
Journal:  Mol Cell Biochem       Date:  2022-02-07       Impact factor: 3.396

8.  Neurological complications of new chemotherapy agents.

Authors:  Alicia M Zukas; David Schiff
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

9.  Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.

Authors:  Elizabeth A Larocque; N Naganna; Clement Opoku-Temeng; Alyssa M Lambrecht; Herman O Sintim
Journal:  ChemMedChem       Date:  2018-05-22       Impact factor: 3.466

Review 10.  The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Priyanka A Pophali; Mrinal M Patnaik
Journal:  Cancer J       Date:  2016 Jan-Feb       Impact factor: 3.360
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.